Other EGFR-targeted treatment options, such as the monoclonal antibodies cetuximab and panitumumab, as well as the TKIs afatinib, gefitinib or neratinib, have been approved for (metastatic) non-small cell lung cancer, HER2-positive breast cancer and (metastatic) colorectal cancer bearing no KRAS mutation. Here, KRAS is linked to non-small cell lung carcinoma.